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Development of clinically relevant in vivo
metastasis models using human bone discs
and breast cancer patient-derived
xenografts
Diane Lefley1†, Faith Howard1†, Fawaz Arshad1, Steven Bradbury1, Hannah Brown1, Claudia Tulotta1, Rachel Eyre2,
Denis Alférez2, J. Mark Wilkinson1, Ingunn Holen1, Robert B. Clarke2 and Penelope Ottewell1*
Abstract
Background: Late-stage breast cancer preferentially metastasises to bone; despite advances in targeted therapies,
this condition remains incurable. The lack of clinically relevant models for studying breast cancer metastasis to a
human bone microenvironment has stunted the development of effective treatments for this condition. To address
this problem, we have developed humanised mouse models in which breast cancer patient-derived xenografts
(PDXs) metastasise to human bone implants with low variability and high frequency.
Methods: To model the human bone environment, bone discs from femoral heads of patients undergoing hip
replacement surgery were implanted subcutaneously into NOD/SCID mice. For metastasis studies, 7 patient-derived
xenograft tumours (PDX: BB3RC32, ER+ PR+ HER2−; BB2RC08, ER+ PR+ ER2−; BB6RC37, ER− PR− HER2− and BB6RC39, ER+
PR+ HER2+), MDA-MB-231-luc2, T47D-luc2 or MCF7-Luc2 cells were injected into the 4th mammary ducts and metastases
monitored by luciferase imaging and confirmed on histological sections. Bone integrity, viability and vascularisation were
assessed by uCT, calcein uptake and histomorphometry. Expression profiling of genes/proteins during different stages of
metastasis were assessed by whole genome Affymetrix array, real-time PCR and immunohistochemistry. Importance of IL-1
was confirmed following anakinra treatment.
Results: Implantation of femoral bone provided a metabolically active, human-specific site for tumour cells to metastasise to.
After 4 weeks, bone implants were re-vascularised and demonstrated active bone remodelling (as evidenced by the
presence of osteoclasts, osteoblasts and calcein uptake). Restricting bone implants to the use of subchondral bone and
introduction of cancer cells via intraductal injection maximised metastasis to human bone implants. MDA-MB-231 cells
specifically metastasised to human bone (70% metastases) whereas T47D, MCF7, BB3RC32, BB2RC08, and BB6RC37 cells
metastasised to both human bone and mouse bones. Importantly, human bone was the preferred metastatic site especially
from ER+ PDX (100% metastasis human bone compared with 20–75% to mouse bone), whereas ER-ve PDX developed
metastases in 20% of human and 20% of mouse bone. Breast cancer cells underwent a series of molecular changes as they
progressed from primary tumours to bone metastasis including altered expression of IL-1B, IL-1R1, S100A4, CTSK, SPP1 and
RANK. Inhibiting IL-1B signalling significantly reduced bone metastasis.
Conclusions: Our reliable and clinically relevant humanised mouse models provide significant advancements in modelling
of breast cancer bone metastasis.
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Introduction
Bone metastasis in breast cancer is a significant clinical
problem, with up to 80% of patients with late-stage dis-
ease developing secondary skeletal involvement. Current
treatments for bone metastasis are palliative and do not
provide life-prolonging benefit, and a high proportion of
patients experience bone complications including pain,
fracture, nerve compression and hypercalcaemia [1].
The development of new treatment strategies for this
group of patients requires a better understanding of the
molecular mechanisms behind metastasis to bone. It is
widely accepted that metastatic lesions are formed by suc-
cessive genetic and epigenetic changes in both tumour
cells and the microenvironment, driving a process termed
‘the metastatic cascade’ [2]. Epithelial cells from the pri-
mary tumour undergo epithelial-mesenchymal transition
(EMT). During this process, tumour cells acquire a migra-
tory and invasive phenotype that allows them to invade lo-
cally through the surrounding stroma before entering the
circulation directly or via the lymphatic’s. Dissemination
through the circulation then requires adaptive changes for
survival and evasion of immune responses, prior to ex-
travasation into secondary sites. Secondary tumours occur
by metastatic cell survival, proliferation and vascularisa-
tion to support the growing tumour foci [3].
Certain properties of metastatic cancer cells (e.g. migra-
tion and invasion) can be studied relatively quickly/cheaply
using in vitro systems [4], but these models do not provide
the tissue-specific context or reflect the multiple biological
processes, cell types and molecular interactions involved.
An ideal model should recapitulate as many steps of the
metastatic cascade as possible, in order to facilitate the de-
velopment of novel therapeutic strategies. Traditional ex-
perimental metastasis models involve the study of mouse
tumours that colonised the skeleton [5, 6]; however, there
are fundamental biological differences between humans
and mice. Enhanced metabolic activity and longer telo-
meres in mice compared to humans are just two examples,
which determine oncogenesis and translate to phenotypic
differences [7]. These differences also include the develop-
ment of cancer in mesenchymal tissues in mice, whereas
human tumours arise mainly from epithelial cells [7].
Mouse mammary tumours are hormone-independent, re-
quiring lower levels of oestrogen/progesterone to support
their growth in comparison to the majority of human breast
tumours that are the hormone responsive [8]. Mouse tu-
mours are also significantly less likely to metastasise to
bone compared with human tumours (reviewed in [7]).
Xenograft models whereby human cells/tissues are
injected into immunodeficient mice are now routinely
used. Whilst subcutaneous tumour implantation is con-
venient and allows the study of genetically manipulated
cells or mice, it does not provide the optimal micro-
environment for modelling metastatic disease, including
spreading to bone. Direct orthotopic implantation of
tumour cells into bone (most commonly the tibia) over-
comes this problem by introducing a large number of
tumour cells directly into bone, allowing the study of
molecules involved in tumour growth at this site. How-
ever, intratibial injections are technically demanding and
invasive, and the piercing of the cortex and displacement
of the bone marrow induces a healing response, thereby
changing local bone metabolism and hence the bone
microenvironment [9]. It also circumvents the early
steps of bone homing and invasion. The most commonly
used bone metastasis model relies on intravascular injec-
tion of human cancer cells either via the left cardiac ven-
tricle or the tail vein, with the success of the latter
relying on specific bone homing cell lines [10, 11]. Al-
though useful for investigating organ-specific extravasa-
tion, survival and proliferation, this method bypasses the
early molecular cues that may be responsible for initi-
ation of metastasis from the primary tumour. The use of
bone metastatic cell lines selected by multiple in vivo
passages of tumour cells isolated from bone metastases
may also fail to replicate the changes that are associated
with bone homing. These models are therefore consid-
ered models of organ colonisation and growth, rather
than metastasis.
A more clinically relevant metastasis model may
thus be provided by the use of orthotopic transplant-
ation, where human breast cancer cells are implanted
into murine mammary tissue and subsequent second-
ary tumour growth detected in a range of tissues. The
ability to study all stages of the metastatic cascade is
an advantage, and this model has been shown to
more faithfully mimic human tumour histology, gene
expression profiles and therapeutic responsiveness
[12]. However, it does not represent organ-specific
metastasis, and there is considerable variation in the
frequency and site of secondary tumour growth.
Current understanding of the metastatic process also
proposes a role for the metastatic niche for the initi-
ation of metastatic cells, as well as their homing and
colonisation potential at secondary sites (reviewed in
[13]). Species differences may therefore influence the
ability of the primary tumour to prepare/initiate a fu-
ture metastatic niche. In an attempt to develop more
clinically relevant models, in which tumour cells me-
tastasise to a metastatic tissue of human origin, re-
searchers have developed “humanised” animal models
whereby pieces of human bone are sub-cutaneously
implanted into immunocompromised mice before in-
jection of tumour cells. However, the few publications
in which this model has been used to study breast
[14, 15] and prostate cancer metastasis [16] have re-
ported low tumour take rates in human bone by a
number of cell lines injected via tail vein or via
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orthotopic implantation, with osteotropism seemingly
limited to the SUM1315 breast cancer cell line [14].
In the current study, we have significantly refined the
humanised bone metastasis model to generate the first
patient-derived xenograft (PDX) models of human ER+
and triple-negative breast cancer metastasis to human
bone implants. These models represent all aspects of the
metastatic cascade, including tumour growth at the pri-
mary site, dissemination into the circulation, homing to
the human bone environment and colonisation of hu-
man bone by disseminated tumour cells. Both ER+ and
triple-negative models have a high propensity to metas-
tasise to human bone implants, and the described meth-
odology provides highly reproducible metastasis from
human breast cancer cell lines and PDXs. Using these
refined models, we investigated the molecular changes
that breast cancer cells undergo as they progress
through the different stages of the metastatic process,
demonstrating the usefulness of these models in identi-
fying novel genes/molecules that can be used as poten-
tial biomarkers or therapeutic targets for breast cancer
bone metastasis.
Materials and methods
Animals
All experiments were carried out in 8–10-week-old fe-
male NOD/SCID or NOD/SCIDγ mice (Charles River,
Kent, UK) maintained on a 12-h:12-h light/dark cycle
with free access to food and water. Experiments were
carried out in accordance with local guidelines and with
home office approval under project licences 40/3531 and
70/08964 University of Sheffield, UK.
Cell lines and patient-derived xenografts
Human breast cancer MDA-MB-231-Luc2-TdTomato
(Calliper Life Sciences, Manchester UK), MDA-MB-231
(parental), MCF7 and T47D were originally purchased
from European Collection of Authenticated Cell Cul-
tures (ECACC) and stably transfected to express lucifer-
ase cultured in DMEM + 10% FCS (Gibco, Invitrogen,
Paisley, UK) prior to injection [17]. Cell lines purchased
from commercial sources have been authenticated in-
house using short tandem repeat analysis of 10 loci. All
cell lines were cultured in a humidified incubator under
5% C02 and used at low passage > 20.
A panel of patient-derived xenografts (PDXs) derived
from breast cancer patients consisted of previously charac-
terised BB6RC39 (ER+ PR+ HER2+); BB3RC31, BB3RC32,
and BB2RC08 (ER+ PR+ HER2−); and BB6RC37 and
BB6RC52 (ER− PR− HER2−) breast cancer xenografts that
have not been cultured in vitro [18]. Data and metadata
on PDX models are available in PDX Finder (http://doi.
org/10/1093/nar/gky984, pdxfinder.org http://pdxfinder.
org/) and the EuroPDX data portal (http://dataportal.
europdx.eu). PDXs were frozen in 10% DMSO 90% FCS
in liquid N2 for long-term storage before being revived by
direct subcutaneous implantation of tumour pieces into
female NOD/SCIDγ mice. PDXs were removed once tu-
mours reached 1 cm3 and dissociated into a single-cell
suspension using Miltenyi tumour dissociation buffer
(130-095-929) under constant agitation for 90min at
37 °C. PDXs were transduced to express TdTomato Luc2
via electroporation (using 2-μg plasmid per 2,000,000 live
cells in nucleofectin buffer and Amaxa nucleofector sys-
tem 1 (Lonza, Scientific laboratory Supplies, Nottingham))
before re-injecting 100,000 cells through the 4th nipples
into the mammary gland (MIND model [19]) or left car-
diac ventricle of mice.
Surgical human bone tissue and implantation
Human femoral heads were collected with informed
consent from postmenopausal women with rheumatoid
arthritis undergoing routine total hip replacement sur-
gery under HTA licence 12182, Sheffield Musculoskel-
etal Biobank, University of Sheffield, UK. Trabecular
bone implants (0.5 cm3) were prepared from the femoral
heads of patients undergoing hip replacement surgery.
Briefly, femoral heads were clamped at the femoral neck
into an Isomet 4000 Precision saw (Buehler, Coventry,
UK). Horizontal 5-mm slices were cut using a Precision
diamond wafering blade (Buehler) with the first slice
comprising mainly cortical bone being discarded. Tra-
becular bone implants were excised from the bone slices
using a bone trephine (5-mm diameter) before storing in
sterile PBS at room temperature. Bone implants were
subcutaneously positioned in the left and right flanks of
NOD/SCID mice under isoflurane anaesthesia within 2–
4 h of removal of the femoral head from the patient.
Mice received a single subcutaneous analgesic injection
(15 mg, Vetergesic, Alstoe Animal Health, York) imme-
diately before surgery; plus broad spectrum antibiotic 10
mg/kg (Septrin, Aspen Pharma, Australia) was adminis-
tered by sub-cutaneous injection immediately after bone
implantation and 24 h later.
Time course for bone implant characterisation
NOD/SCID mice (n = 20) were culled 7, 14, 21 and 28
days post human bone implantation (n = 5 per group, 2
implants/mouse) and tissue collected for downstream
analyses. One bone implant was fixed in 4% PFA, one
bone implant was snap frozen in liquid nitrogen and
mouse spleen was harvested in ice-cold sterile PBS for
immediate flow cytometric analysis of B cell populations.
Administration of tumour cells and pharmacological
agents to model bone metastasis
NOD/SCID mice (n = 10/group) underwent bone core
implantation. Four weeks later 5 × 105 MDA-MB-231-
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luc2-TdTomato, T47D or MCF7 cells or 1 × 105 PDX
cells were injected orthotopically or into the 4th mam-
mary ducts in 33% matrigel: 66% PBS: 1% trypan blue,
or 1 × 105 PDX cells were injected via the left cardiac
ventricle. Experiments were carried out 3 separate times
using bone from different donors each time. To facilitate
growth of ER+ tumour cells and PDXs, mice were sup-
plemented with 12 mg/L 17β oestradiol (Sigma Aldrich,
Poole, UK) via their drinking water starting immediately
following injection of tumour cells. For pharmacological
inhibition of IL-1R signalling, mice were administered 1
mg/kg/day anakinra or placebo (control) via subcutane-
ous injection (n = 10/group). Primary tumour growth
and metastases were monitored weekly by IVIS imaging.
Primary tumours from MCF7 or T47D cells were re-
moved by surgical resection once they reached 1 cm3
and metastasis left to develop for 8 weeks. For MDA-
MB-231-luc2-TdTomato and PDXs, mice were culled
when primary tumours reached 1 cm3 or mice lost ≥
10% of their body weight. Samples taken for Affymetrix
gene expression analysis were considered to contain
metastatic cells if a positive signal for metastasis was de-
tected by IVIS. For all other samples and PDXs, metasta-
ses were further confirmed on histological sections by
breast histopathologist Prof. Simon Cross (University of
Sheffield).
Multiphoton microscopy for cell viability and
vascularisation
Cell viability and vascular permeability were assessed
using multiphoton microscopy by the uptake and activa-
tion of calcein AM (Sigma Aldrich). Two mice per group
received 30mg/kg of calcein AM by intraperitoneal in-
jection 24 h prior to culling. Bone cores from injected
mice were frozen in OCT and kept at − 80 °C until ana-
lysis using a Zeiss 510 multiphoton microscope (Zeiss,
UK) and LSM510 software (Zeiss, UK). Briefly, a × 20/
0.8 lens and a chameleon laser were used for bone im-
aging. Calcein was detected using the Argon/488 laser
and lectin using the 633 laser. The scan area utilised a
6 × 6 tile scan with an average Z-stack depth of 100 μm.
Fluorescence-activated cell sorting (FACS) analysis for
detection of human B cells in spleen
The spleen was harvested from each mouse and dissoci-
ated by mincing with a scalpel blade in ice-cold PBS. 1 ×
106 spleen cells were incubated with a cocktail of
mouse-specific CD45-APC (1 μl, for the exclusion of
mouse leukocytes), human-specific CD19-FITC (1 μl,
302205, BioLegend, for the detection of human B cells)
and human-specific IgG-PE (1 μl, 409303, BioLegend).
Analysis was performed using a FACSCalibur™ flow cyt-
ometer (BD Biosciences).
Microcomputed tomography
Analysis of bone volume was carried out using a Skyscan
1172 X-ray–computed microtomograph (Skyscan, Aart-
selaar, Belgium) equipped with an X-ray tube (voltage,
49 kV; current, 200 mA) and a 0.5-mm aluminium filter.
Pixel size was set to 7 μm. For each sample, cross-
sectional images were reconstructed with NRecon
software (version 1.4.3, Skyscan). Volume of interest was
defined on the two-dimensional acquisition images by
drawing a 4-mm circle. Trabecular bone volume fraction
(BV/TV)—the ratio of the volume of bone present (BV)
to the volume of the cancellous space (TV)—was calcu-
lated for 3 mm of the bone. Modelling and analysis were
performed with the use of CTAn (version 1.5.0.2) and
CTvol (version 1.9.4.1) software (Skyscan).
Histology—detection of osteoclasts and osteocytes
Bone implants were fixed in 4% paraformaldehyde and ana-
lysed by uCT prior to decalcification in a solution of 1%
paraformaldehyde/0.5% EDTA in PBS for 4 weeks, chan-
ging the solution at weekly intervals. Bone implants were
embedded in paraffin wax from which 4-μm sections were
cut using a microtome. Osteoclasts were identified by
tartrate-resistant acid phosphatase (TRAP) staining. Briefly,
dewaxed sections were incubated in acetate-tartrate buffer
at 37 °C for 5min followed by incubation in naphthol AS-
BI phosphate, dimethylformamide in acetate-tartrate buffer
for 30min at 37 °C. Sections were placed in a solution con-
taining sodium nitrite, pararosaniline and acetate-tartrate
buffer for 15min at 37 °C, before counterstaining with
haematoxylin. Osteoclasts were quantified per millimetre of
trabecular bone surface from whole sections using a Scan-
Scope digital slide scanner and software (Aperio, CA, USA).
In the same sections, the number of viable osteocytes was
counted and expressed as a percentage of empty lacunae.
Isolation of circulating tumour cells
Whole blood was centrifuged at 10,000g for 5 min, and
the cell pellet re-suspended in 5 ml of FSM lysis solution
(Sigma-Aldrich, Pool, UK) to lyse red blood cells.
Remaining cells were re-pelleted, washed 3 times in PBS
and re-suspended in a solution of PBS/10% FCS. Sam-
ples from 10 mice per group were pooled prior to isola-
tion of TdTomato-positive tumour cells using a MoFlow
High performance cell sorter (Beckman Coulter, Cam-
bridge UK) with the 470 nM laser line from a Coherent
I-90C tenable argon ion (Coherent, Santa Clara, CA).
For gene expression analysis: TdTomato fluorescence
was detected by a 555LP dichroic long pass and a 580/
30 nm band pass filter. Acquisition and analysis of cells
were performed using Summit 4.3 software. Following
sorting, cells were immediately placed in RNA protect
cell reagent (Ambion, Paisley, Renfrew, UK) and stored
at − 80 °C before RNA extraction.
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Gene analysis
Total RNA was extracted using an RNeasy kit (Qiagen)
and manufacturers’ instructions. For Affymetrix array
analysis, RNA was amplified using an mRNA amplifica-
tion kit (Ambion) before being reverse transcribed into
cDNA using Superscript III (Invitrogen AB). cDNA from
MDA-MB-231 cells grow in the mammary ducts that
did not metastasise, MDA-MB-231 cells grow in the
mammary ducts that did metastasise, their correspond-
ing metastases in human bone implants and naïve hu-
man bone from the same patient were pooled into n = 3
per sample, and three sets of pooled samples were hybri-
dised to separate whole genome Affymetrix arrays using
Prime View Gene Expression Arrays (Applied Biosys-
tems) (Raw data available via www.ncbi.nih.gov acces-
sion number GSE137842). Data were analysed using
Qluocore software (www.Qluocore.com) and genetic
pathways for functional annotation were constructed
using DAVID functional annotation tools (https://david.
ncifcrf.gov/tools.jsp). Confirmation of genes whose ex-
pression profiles were central to pathways identified as
being associated with bone metastasis were validated
using cDNA from MDA-MB-231, MCF7 and T47D cells
grown in vitro, cells grown in mammary ducts that did
not metastasise, cells that metastasised from mammary
ducts, circulating tumour cells, their corresponding me-
tastases in human bone implants and naïve human bone
from the same patient on microfluidic plates (plate num-
ber: 2586577, Applied Biosystems). Expression profiles
of genes associated with different stages of the breast
cancer metastasis to bone were confirmed independently
in three samples per group and in primary and human
bone metastases from BB2RC08 and BB6RC37. Relative
mRNA expression of PRRT2 (Hs01005085_g1), HRAS
(Hs00978050 g1), FN1 (Hs01549976 m1), SERPINE 1
(Hs01126606m1), MAPK3 (Hs00385075m1), CDC42
(Hs00918044_g1), MYC (Hs00153408_m1), IL-1B
(Hs00174097_m1), Caspase 1 (Hs00354836_m1), AKT1
(Hs00178289_m1), S100A4 (Hs00243202_m1), CTSK
(Hs00166156_m1), MAPK1 (Hs01046830_ml), LAMB1
(Hs01055967_m1), SPP1 (Hs00959010_m1), IL1R1
(Hs00991010_m1), BCL2 (Hs00608023_m1), IKBKB
(Hs00233287_m1), CLDN1 (Hs00221623_m1), CDK2
(Hs01548894_m1), BCL2L1 (Hs00236329_m1), IL-1Ra
(Hs00893626_m1), JUP (Hs00233287_m1), TNFRSF11A
(Hs00269492_m1) and CTSK (Hs00166156_m1) were
compared with the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH; Hs99999905_m1).
To assess the expression profile of genes associated with
either human or mouse origin bone and as osteoclast
and osteoblast markers, RNA was reverse transcription
using Superscript III (Invitrogen) before analysis using
Taqman gene expression assays. Relative mRNA expres-
sion of CTSK (Hs00166156_m1 and Mm01255862_g1),
RANKL (Hs00243522_m1 and Mm00437135_m1), VEGF
(Hs00900054_m1 and Mm), ACP5 (Hs00356261_m1),
ALPL (Hs01029144_m1) and OPG (Hs00900358_m1)
were compared with the housekeeping gene GAPDH
(Hs99999905_m1 and Mm99999915_g1). Expression of
ER/PR/HER2 were confirmed in PDX samples using Taq-
man gene expression assays for ESRRG (Hs00976243_
m1), PGR (Hs01556702) and ERBB2 (Hs01001580_m1)
and CT compared with GAPDH. All PCR assays were per-
formed using an ABI 7900 PCR System (Perkin Elmer,
Foster City, CA) and Taqman universal master mix (all re-
agents were purchased from Applied Biosystems via Ther-
mofisher, UK). Fold change in gene expression between
treatment groups was assessed by directly inserting CT
values into Data Assist V3.01 software (Applied Biosys-
tems), and changes in gene expression were only analysed
for genes with a CT value of ≤ 25.
Immunohistochemistry
The presence of osteoblasts was detected by immunohis-
tochemistry using an antibody specific for human osteo-
calcin (M184, Takara Bio Inc., Japan). To determine the
origin of blood vessels in the re-vascularised bone im-
plants, a dual immunofluorescence protocol using
species-specific CD31 antibodies was performed to de-
tect endothelial cells; human-specific CD31 (1:400,
ab76533, Abcam, UK) and mouse-specific CD31 (1:400,
ab56299, Abcam, UK). To establish whether genetic al-
terations observed between PDXs growing in the fat pad
and those that had metastasised to bone were translated
into changes in protein expression immunohistochemis-
try for IL-1B (1:200, ab2105, Abcam), IL1R1 (1:200,
ab154524, Abcam), S100A4 (1:500, ab40722, Abcam,
hRAS (1:200, ab97488, Abcam), DKK (1:200, Ab38594,
Abcam), Gamma Catenin (1:25, 2309, Cell signalling),
Fibronectin (1:50, ab32419, Abcam). Staining was visua-
lised with corresponding biotin-conjugated secondary
antibodies (Vector Laboratories, 1:200) and either avidin
FITC (mouse) or avidin TRITC (human) (Vector
Laboratories).
Statistical analysis
All data are expressed as mean ± SEM. Statistical signifi-
cance was tested for two-tailed paired or unpaired t test
as appropriate using Prism 7 software (GraphPad, La
Jolla, CA, USA). Statistical significance was defined as P
less than or equal to 0.05.
Results
Bone viability following xenotransplantation
To characterise the early stages of human trabecular
bone engraftment following subcutaneous implantation
in NOD/SCID mice, a time course was performed
whereby cohorts of animals were culled at weekly
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intervals for 4 weeks following bone implantation (n = 5
per time point) (Fig. 1a). Bone cores were isolated and
histological and gene expression analyses were per-
formed to investigate bone viability and integrity.
Bone viability was investigated by quantification of os-
teocytes as well as functional labelling of viable cells
visualised by multiphoton microscopy of calcein uptake
(Fig. 1b, c). Despite positive calcein labelling, viability of
the human bone was reduced as detected by the loss of
osteocytes. There was a 57% fall in viable osteocytes
(measured by quantitation of empty lacunae) by day 7
compared to day 0 controls (p < 0.0001). This was main-
tained at all later time points and did not decrease fur-
ther. These results support that there is a substantial
loss of bone cell viability in the initial stages following
in vivo implantation, likely in part due to the lack of vas-
cularisation of the bone cores and damage to the tissue
during preparation of the bone implants. Nevertheless,
the integrity of the bone cores was maintained through-
out the time course experiment. There was no signifi-
cant difference between the bone volume/tissue volume
ratios of engrafted bone cores at any time point com-
pared to day 0 baseline controls (Fig. 1d).
Detection of functional bone cells in the bone cores
Bone forming osteoblasts and bone resorbing osteo-
clasts are considered to be components of the bone
metastatic niche; we therefore assessed the presence
and activity of these two key cell types using a com-
bination of immunohistochemistry and gene expres-
sion. Osteoclasts on the bone core surfaces were
clearly identified by TRAP staining together with their
unique multi-nucleated morphology (Fig. 1e (i)). Fol-
lowing xenotransplantation, their number fell during
the first week but steadily increased back to baseline
control level by week 4 (NS, Fig. 1e (ii)). Species-
specific gene expression of the osteoclast marker
CTSK suggests that the majority of this recovery is
attributed to repopulation by mouse-derived osteo-
clasts (Fig. 1e (iii)); however, functional human osteo-
clasts were still identified by detectable human CTX
secretion in serum samples collected from 5 mice at
day 28. Osteoblasts also remained present on the sur-
face of human bones for the duration of the experi-
ment (Fig. 1e (i)). Numbers of osteoblasts reduced 14
days after bone implantation (p < 0.001) but returned
to normal levels by day 28 (Fig. 1e (ii)). This was due
to increased recruitment of mouse osteoblasts; how-
ever, human osteoblasts remained present and could
be detected by RANKL expression in bone for the
28-day time period of the experiment (Fig. 1e (iii)).
These data indicate that by day 28, bone structure is
normalised and is being actively turned over by both
mouse and human osteoclasts and osteoblasts.
Revascularisation and human B cell production following
xenotransplantation
Functional revascularisation of the bone core was con-
firmed by multiphoton microscopy of bone cores iso-
lated from animals that had received an i.v. injection of
Alexa-conjugated lectin prior to cull (Fig. 2a–c). To de-
termine the species origin of endothelial cells respon-
sible for vascular remodelling, dual immunofluorescence
was performed on sections using both mouse- and
human-specific CD31 antibodies. Day 0 controls show
the presence of human CD31+ endothelial cells lining
blood vessel walls with no cross-reactivity from the
mouse CD31 antibody (Fig. 2d–k). The total number of
CD31+ blood vessels was counted from 10 fields per
bone core section for each time point. There was no loss
in the number of vessels detected over time compared to
day 0 controls with a mean range of 30–40 vessels per
section. Vessels that stained positive for just human
CD31 were present in bone sections for 7 days post im-
plantation but fell significantly between day 14 and the
end of the study (p < 0.0001). In contrast, vessels that
stained positive for both human and mouse CD31 be-
came evident from day 14 and comprised of 81% of all
vessels (Fig. 2l (i, ii)), and these levels of dual stained
vessels remained high (93% and 81%) at days 21 and 28
respectively. In contrast, no vessels staining exclusively
for mouse CD31 were detected at any time point. To
further establish the species derivation of the blood ves-
sels, gene expression of VEGF in the implanted bone
cores was quantified using human- and mouse-specific
primers (Fig. 2l (iii)). The pattern of expression over the
time course mirrored that of the immunofluorescent
staining, with human VEGF expression decreased 1 week
following implantation (mean ΔCT 5.7 ± 0.2 vs. 2.5 ± 0.5
at day 0 and day 7 respectively, p < 0.001). A concomi-
tant increase in mouse VEGF was detected during the
same time period (mean ΔCT − 4.2 ± 0.5 vs. 3.8 ± 0.4 at
day 0 and day 7 respectively, p < 0.05). An equal level of
murine and human VEGF expression was detected for
the remainder of the study, suggesting that the vascular-
isation of the implanted bone discs is a consequence of
angiogenesis and not vasculogenesis by the murine
vasculature.
In addition, the presence of human B cells in the
mouse spleen was investigated to support not only the
ability of the bone core to re-vascularise but as evidence
of the transfer of cells from one organ site to another,
important for modelling metastasis.
Differentiation of B cells begins in the bone marrow
and is completed in the spleen. Therefore, viability of
the human bone cores and its bone marrow was first de-
termined by the identification of human B cells in the
mouse spleen (Fig. 3). Single-cell suspensions from the
spleen were first separated by flow cytometry into a
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mouse CD45-negative population. From this population
human B cells were identified by double-labelling for hu-
man CD19 and human IgG. The number of human B
cells detected in spleen cell suspensions increased with
time, representing 0.19, 0.13, 0.55 and 0.94% of the total
number of cells at days 7, 14, 21 and 28 respectively,
reaching significance by day 7 (p < 0.05).
Metastasis of breast cancer cell lines to human bone
implants
MDA-MB-231-TdTomato Luc2 breast cancer cells were
injected orthotopically into the 4th mammary fat pads of
NOD/SCID mice 4-weeks after implantation of human
bone discs using the same protocol set out by Kupper-
wasser et al. [14]. The orthotropic engraftment resulted
in tumour growth at the primary site in 90% of animals
and spontaneous metastasis to human bone in 20% (data
not shown). Changing the tumour implantation method
to intra-ductal tumour cell injection, where breast can-
cer cells were injected via the 4th nipples into the mam-
mary ducts [19] increased percentage of spontaneous
metastasis to 30% (Fig. 4a). We have previously shown
that sub-chondral human femoral bone is more meta-
bolically active than spongy bone [20]; when only sub-
chondral bone was used, metastasis to these implants
further increased to 70% (Fig. 4b). MDA-MB-231-TdTo-
mato Luc2 cells specifically metastasised to live human
bone implants; when bone was de-vitalised by boiling
before implantation, tumour cells did not metastasise to
this site (Fig. 4c, d) and no metastasis to mouse organs
were observed. We therefore carried out all future ex-
periments using sub-chondral bone to mimic the human
bone metastatic site, and tumour cells were administered
via intra-ductal injection.
The majority of breast cancers that metastasise to
bone are ER+, and in vivo models that represent this
condition are lacking. We therefore tested the ability of
ER+ MCF7 and T47D cells to metastasise to human
bone implants. In NOD/SCID mice, we were unable to
grow MCF7 or T47D cells in the mammary ducts with-
out oestrogen supplementation (data not shown).
Oestrogen has bone anabolic effects that have been
shown to increase the metastatic potential of ER+ breast
cancer cell lines [17]. To minimise these effects, mice
were supplemented with the lowest dose of oestradiol
that we found to be sufficient to support growth of the
primary tumour, 12 mg/L. Using this dose of oestradiol
resulted in primary tumour growth in 80% of mice
injected with T47D cells and 70% of mice injected with
MCF7 cells; however, no metastases were detected from
either of these cell lines 5 weeks after injection. Follow-
ing excision of the primary tumours, metastases devel-
oped in the human bone implants (50–60% of animals)
and in mouse bone (40–50%) over an 8-week time
period (data for T47D cells shown in Additional file 1:
Figure S1).
Metastasis of PDXs to human bone implants
Having established that human breast cancer cell lines
preferentially metastasise to a human-specific site (hu-
man bone implant), we then developed PDX models.
We hypothesised that breast cancer PDXs may also
metastasise to this site, providing us with a model
that more closely resembles human disease. A selec-
tion of PDXs (ER− PR− HER2−, ER+, PR+ HER2−,
ER+ PR− HER2− and ER− PR− HER2−) that have
never been cultured in vitro but have been propa-
gated in NOD/SCIDy mice were used to increase the
likelihood of tumour take (Table 1) [18]. To model
spontaneous metastasis, tumours were injected into
the 4th mammary ducts, and to mimic direct seeding
from the blood, tumour cells were injected into the
left cardiac ventricle 4 weeks after implantation of
human bone. Intra-ductal injection of PDXs resulted
in metastasis to human bone, mouse bone, and the
lung with different frequencies depending on tumour
type (Table 2). ER+ PDXs that metastasised to bone
(BB3RC32 and BB2RC08) preferentially metastasised
to human bone over mouse bone (100% vs. 75%;
100% vs. 20% respectively) whereas triple-negative
PDXs preferentially metastasised to the lung com-
pared with bone (100% vs. 20% mouse and 20%
human).
Seeding PDX cells directly into the blood slightly re-
duced metastases to human bone in ER+ PDXs (100 to
80%, in mice injected with BB3RC32 or BB2RC08 cells
via intra-ductal injection compared with intra-cardiac)
and increased metastasis in triple-negative BB6RC37
(See figure on previous page.)
Fig. 1 Viability of human bone xenograft following implant into NOD SCID mice. Two 0.5-cm3 pieces of human femoral head were implanted
subcutaneously into 8-week-old female NOD SCID mice (n = 5/group). Animals were culled and bone implants removed 0, 7, 14, 21 and 28 days
following implantation for analysis of viability (a). Percentage of viable osteocytes was assessed following Giemsa staining (b). Uptake of fluorescently
labelled calcein by viable cells 0 and 28 days following implantation of bone was detected by multiphoton microscopy (c). Structure of bone was assessed
by uCT and bone integrity shown as % bone volume compared with total tissue volume (BV/TV%) (d). Effects on osteoclast and osteoblast numbers and
origin are shown in (e). (i) X60 photomicrographs of osteoclasts and osteoblasts lining human bone 28 days after implantation. (ii) Numbers of osteoclasts
and osteoblasts per mm of bone surface, and (iii) origin of these cells as identified by expression of mouse and human CTSK (osteoclasts) and RANKL
(osteoblasts/osteocytes) normalised to GAPDH. All graphs show mean ± SEM from 5 mice per time point. Data represents mean ± SEM with statistical
significance determined by one-way ANOVA. *p< 0.01, **p< 0.001, ***p< 0.001 compared with 0 h control
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from 20 to 30%. However, intra-cardiac injection of
PDXs consistently increased metastases in mouse bone
(Table 2).
Histological examination of the tumours revealed
phenotypical differences between tumour cells growing
at the primary site and those growing in the human
bone disc. Irrespective of their sub-type, PDXs growing
in the primary site are epithelial in appearance whereas
in the human bone these same cells take on a fibroblas-
tic appearance (Fig. 5), suggesting that cells undergo a
distinct set of molecular changes that enable them to
grow in this altered metastatic environment. These
Fig. 2 Vascularisation of human bone xenografts following implantation into NOD/SCID mice. Representative 3D reconstructions of bone architecture
(a), tomato-conjugated lectin bound to carbohydrates on the luminal surfaces of blood vessels (b) and their merged location within the bone (c).
Determination of species origin of endothelial cells is shown in panels d–k, representative immunofluorescent images of bone sections on day 0 (d–g)
and day 28 (h–k). Single-channel DAPI (d and h), FITC-conjugated mouse CD31 (e and i), TRITC-conjugated human CD31 (f and j) and merged dual
stained images (g and k). Total number of blood vessels present in 10 fields per bone was unchanged over the time course. Presence of single stained
human blood vessels decreased significantly from day 14 (l (i)), but a concomitant increase in dual stained vessels was detected (l (ii)). Gene expression
of human and mouse VEGF confirmed the immunofluorescent time curve (l (iii)). Data represents mean ± SEM with statistical significance determined
by one-way ANOVA. ***p < 0.0001
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molecular changes did not result in altered hormone re-
ceptor status, all tumours displayed the same ER/PR/
HER2 phenotype in both primary and metastatic sites
and these were representative of the phenotypes de-
scribed when the tumours were originally isolated from
patients (Additional file 2: Figure S2) [18]. All PDXs that
formed metastases in mouse bones produced lytic le-
sions (Fig. 5). Patients with breast cancer bone metasta-
ses develop lytic lesions; therefore, our data suggest that
PDXs behave in a similar manner in mouse and in
humans.
Cancer cells undergo molecular changes associated with
bone metastasis
Research into molecular mechanisms that drive breast
cancer bone metastases has been hampered by lack of
available clinical material from metastatic sites for study.
Bone biopsies are rarely taken from patients with breast
cancer, and the quality of this material is often poor
resulting in there being few matching pairs of primary
breast tumour and the corresponding bone metastases
being available for research. Therefore, we used our
humanised models of breast cancer metastasis to deter-
mine the molecular changes that occur in tumours dur-
ing the different stages of metastasis. Whole genome
Affymetrix arrays identified 50 genes that were altered in
expression between MDA-Td Tomato tumours growing
in the mammary duct that subsequently metastasised to
human bone implants, compared to those that did not
metastasise (Additional file 4: Table S1). When meta-
static mammary MDA-Td Tomato tumours were com-
pared with their resulting bone metastasis and naïve
human bone, 1261 genes were altered in expression. Im-
portantly, the gene expression profile of naïve bone im-
plants, isolated from the same donor, was excluded from
the equation before downstream analysis. Analysis using
Fig. 3 Evidence for functional activity of vasculature in bone implants. The spleen of NOD/SCID mice implanted with human bone was dissociated for
the detection of human B cells disseminated (n = 5/group). Single-cell suspensions were labelled with antibodies specific for human IgG-PE and CD19-
FITC and mouse CD45. FACS scatter plots were gated for all viable cells (R1), then mouse CD45-negative cells (R2). R5 from each spleen sample was
plotted as a histogram for human CD19+ IgG+ cells for each time point. Data represents mean ± SEM, statistical significance determined by one-way
ANOVA, *p < 0.01, **p < 0.001
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Fig. 4 Effects of bone viability on breast cancer metastasis. Eight-week-old female NOD/SCID mice were implanted with femoral bone (mixed,
spongy and subchondral) (a), subchondral only (b) or subchondral bone that had been devitalized prior to implantation (c). Four weeks after
implantation of bone, all mice received injections of MDA-MB-231 breast cancer cells into mammary ducts 4 and 9; primary tumour growth and
metastasis to human bone implants can be seen in a and b. Histogram (d) represents mean ± SEM of percentage of mice that developed
metastases in human bone implants from 3 independent experiments each containing 10 mice/group, statistical significance determined by one-
way ANOVA. **p < 0.001; ND, not detected
Table 1 Summary of PDX models and metastatic potential. PDX breast cancer sub-types and metastasis status of patients from
which cells were isolated
Model
name
Pathology Type Grade PDX model creation Metastasis status/site in patient
BB3RC31 IDC (PE) Late breast
cancer
2 Cells isolated from
pleural effusion
Lung, liver and peritoneum at time of drain
BB3RC32 IDC (Asc) Late breast
cancer
2 Cells isolated from
ascetic fluid sample
Liver, lung and peritoneum at time of drain.
BB2RC08 IDC Late breast
cancer
Unknown Created from primary
breast tumour
No metastasis or recurrence to date.
BB6RC39 IDC Early breast
cancer
2 Created from primary
breast tumour
No metastasis or recurrence to date.
BB6RC37 IDC Early breast
cancer
3 Created from primary
breast tumour
No metastasis at time of PDX generation. Patient since diagnosed with
metastasis to bone, liver and peri-pancreatic node.
BB6RC52 IDC Early breast
cancer
3 Created from primary
breast tumour
No metastasis at time of PDX generation. Patient since diagnosed with
brain metastasis.
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Table 2 Summary of PDX models and metastatic potential. PDX take rate and sites of metastasis following intraductal injection into
NOD SCID mice
Model
name
Receptor status Primary
tumour
growth
Metastasis from primary tumour Metastases from intra-cardiac injection
Mouse bone Human bone Lung Mouse bone Human bone Lung
BB3RC31 ER+ PR+ HER2− 100% 0% 0% 60% NT NT NT
BB3RC32 ER+ PR+ HER2− 80% 75% 100% 70% 80% 80% 40%
BB2RC08 ER+ PR+ HER2− 100% 20% 100% 60% 40% 80% 80%
BB6RC39 ER+ PR+ HER2+ 0% 0% 0% 0% NT NT NT
BB6RC37 ER− PR− HER2− 100% 20% 20% 100% 30% 30% 100%
BB6RC52 ER− PR− HER2− 40% 0% 0% 0% NT NT NT
Fig. 5 Effects of intraductal injection of breast cancer PDX on metastasis to human bone implants. Intraductal injection of a sub-set of breast
cancer PDX into NOD/SCID mice pre-implanted with human subchondral bone results in metastasis to human/mouse bone. Representative
photomicrographs (× 60) of primary tumour sections and human bone sections are shown in (a and b respectively) and uCT images of mouse
tibiae are shown in (c). Human bone metastases in mice from which representative H&E images are shown are outlined in orange squares.
Metastases in mouse bone from which uCT images are shown are highlighted in green squares, and lesions in mouse tibiae are outlined
in yellow
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DAVID pathway mapping software identified 11 primary
pathways associated with bone metastasis, with
cytokine-cytokine receptor interactions being the most
prominent pathway altered between tumours growing at
the primary site and their resulting metastatic deposits
(Additional file 3: Figure S3). The expression profile of
genes that are central to one or more of these pathways
were assessed by real-time quantitative PCR in MDA-Td
and T47D cells grown in vitro, isolated from mammary
tumours that did not metastasise, mammary tumours that
did metastasise, circulating tumour cells and metastases
isolated from human bone implants (Tables 3 and 4). The
expression profile of genes altered between primary tu-
mours and bone metastasis were further investigated in a
triple-negative (BB2RC32) and an ER+ (BB2RC08) PDX
model of metastasis to human bone, to identify common
genes whose expression are altered as tumour cells move
from the primary site to bone (Fig. 6). Using this method
of selection, we identified 5 genes that are central to path-
ways involved in metastasis that were changed in all
triple-negative and ER+ breast cancers tested, MYC,
CLDN1, IL-1B, CTSK and TNFRSF11A.
We next established if changes in gene expression cor-
related with altered protein expression. Immunohisto-
chemistry for S100A4, Fibronectin, RAS, IL-1B, IL-1R1
and γ Catenin was performed on mammary tumours
and metastases in human bone implants. These selected
proteins were chosen because they were predicted to be
altered in either ER+ BB2RC08, triple-negative BB6RC37
or both of these PDXs and have previously been associ-
ated with bone metastasis [10, 11]. The calcium-binding
protein S100A4 and cell adhesion protein fibronectin
were both expressed at low levels in primary mammary
tumours and increased in bone metastasis. The small
GTPase RAS appeared to be unaltered between primary
tumours and bone metastases in BB2RC08 cells and
marginally decreased in BB6RC32 cells. Interestingly, the
pro-inflammatory cytokine IL-1B and its receptor IL1R1
were increased in bone metastases compared with pri-
mary tumours in ER+ BB2RC08 cells but appeared to
decrease in ER-ve BB6RC37 cells, and similar pattern
was observed with the cell-cell adhesion molecule γ Ca-
tenin. Taken together, our data suggest that in our
humanised model of breast cancer bone metastasis
Table 3 Genetic changes incurred during different stages of breast cancer metastasis to bone in triple-negative MDA-MB-231 cells.
ND not detectable, switched on only detected in the comparison group, NT not tested
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tumour cells undergo specific molecular alterations as
they progress through different stages of the metastatic
cascade.
IL-1 signalling is important driver of bone metastasis
We have previously demonstrated that IL-1B in primary
tumours correlates with future relapse in distal organs
including bone in breast cancer patients [10] and have
now demonstrated that IL-1B is altered between primary
tumours and bone metastasis in cell lines and PDXs (Ta-
bles 3 and 4 and Fig. 6). We, therefore, investigated the
importance of IL-1 signalling in promoting bone metas-
tasis in our humanised models. Affymetrix array and
real-time PCR analysis reviled significantly increased IL-
1B in human bone discs implanted into mice 4-weeks
after intra-mammary injection of tumour cells into the
mammary ducts compared to human bone discs isolated
from mice that did not receive injections of tumour
cells. Il-1B increases 118 +/− 36 fold in human bone iso-
lated from mice injected with MDA-Td Tomato cells
that did not metastasise and 371+/− 88 fold in bone iso-
lated from mice injected with MDA-Td Tomato cells
that did metastasise compared with bone isolated from
mice that were not injected with tumour cells (Fig. 7a).
Treating mice with 1mg/kg/day of the IL-1Ra anakinra
reduced numbers of mice that developed metastasis in
human bone implants from (57.14%) to (0%) (Fig. 7b).
These data highlight the importance of IL-1 signalling in
development of bone metastasis.
In conclusion, our models provide valuable pre-clinical
tools to study breast cancer bone metastasis and identify
mechanisms driving this disease in patients. This model
can be used to test pharmacological approaches to stop
breast cancer metastasis, allowing transition from bench
to bedside.
Discussion
Modelling human breast cancer metastasis to bone for the
development of future therapies relies on recapitulating
every step in the metastatic cascade, as well as incorporat-
ing a species-specific microenvironment for secondary
tumour colonisation. In the current study, we have devel-
oped the first PDX models of ER+ and ER- breast cancers
that grow at the primary site and spontaneously
Table 4 Genetic changes incurred during different stages of breast cancer metastasis to bone in ER+ T74D cells. ND not detectable,
switched on only detected in the comparison group, NT not tested
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Fig. 6 (See legend on next page.)
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metastasise to a human bone environment. Breast cancer
cells utilised in these models undergo clinically relevant
molecular changes as they progress through the metastatic
process. Furthermore, molecules identified as metastatic
drivers in this model can be used to predict future relapse
in bone in breast cancer patients [10], highlighting the po-
tential impact of this humanised model system in deliver-
ing translatable data from the laboratory to the clinic.
Researchers have previously attempted to develop
mouse models, such as the humanised model described
here, to represent human breast cancer metastasis to a hu-
man bone environment. However, low rates of metastasis
and the use of just one triple-negative breast cancer cell
line (SUM1315) [14, 21] suggest underlying problems with
this approach. In an attempt to increase rates of metasta-
sis, researchers modelling prostate cancer have used foetal
bone [16, 21]. This bone differs significantly in compos-
ition to adult bone including large numbers of stromal
cells and an absence of plasma cells [22]. Moreover, there
are ethical considerations using this material, and
metastasis rates remain low. These difficulties have led to
exploration of using artificial scaffolds to mimic the meta-
static bone environment [23–25]. Our previous research
and research performed by other laboratories have estab-
lished the importance of bone-bound cytokines and
growth factors in bone metastasis, as well as the need for
viable, metabolically active bone cells (osteoclasts, osteo-
blasts and osteocytes) to facilitate bone turnover and pro-
mote the vicious cycle of cancer-induced bone disease [20,
26]. Artificial scaffolds do not fully represent the human
bone environment: the lack of human-specific growth fac-
tors bound within the bone matrix and limited representa-
tion of cell types found in bone do not allow complete
recapitulation of tumour cell-bone cell interactions that
occur during the metastatic process [20]. We have there-
fore focused our efforts on developing a reliable mouse
model of human breast cancer metastasis to human bone,
in which ER+ and ER-ve breast cancer cell lines and PDXs
spontaneously metastasise to adult human bone implants
with high efficiency and reproducibility.
(See figure on previous page.)
Fig. 6 Gene and protein expression in primary tumours and matched bone metastases from ER+ and ER− PDX. a Fold change in gene expression
from RNA isolated from human bone metastatic deposits compared with the corresponding primary PDXs. Data shown are mean ± SEM for 2
independent repeats of 3 replicates. **p < 0.001, ***p < 0.0001. b Photomicrographs of primary tumours and metastases in human bone implants
following immunohistochemical detection of S100A4, Fibronectin, Ras IL-1B, IL1R1 and γ Catenin. All data shown are from ER+ PR+ HER2− BB2RC08
and ER− PR− HER2− BB2RC37 PDXs
Fig. 7 IL-1B signalling drives breast cancer metastasis to bone. a Gene expression of IL-1B in human bone implants isolated from NOD SCID mice
4 weeks after intraductal injection of MDA-Td Tomato cells. Data shown are from human bone implants bones isolated from mice in which MDA-
Td Tomato cells did not metastasise and from human bone implants with MDA-Td Tomato metastases compared with bone from the same
patient isolated from a mouse not injected with breast cancer cells. Data shown are mean ± SEM for n = 5–10 mice per group. Statistical significance
determined by one-way ANOVA, *p < 0.01, **p < 0.001, ***p < 0.0001. b Effects of inhibiting IL-1 signalling on metastasis to human bone implants.
MDA Td Tomato cells were othrotopically injected into NOD SCID ϒ mice 4 weeks after implantation of human bone. Mice were randomised to
receive 1mg/kg/day anakinra or placebo. Percentage of animals with metastasis in human bone was quantified 8 weeks post tumour cell injection.
Data shown are from 7 to 10 mice per group
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Architectural and cellular composition of trabecular
bone varies between patients and is dependent upon a
number of factors, including direct mechanical stimuli
but also age and sex of individuals, nutrition, co-
morbidities, use of medication and the level of physical
activities that affect bone metabolism [27]. For the
current study, we, therefore, selected to use bones from
post-menopausal women (average age 63, without previ-
ous exposure to anti-resorptive drugs) undergoing total
hip replacement surgery as a result of rheumatoid arth-
ritis, having previously shown that variability in trabecu-
lar bone content is low in these patients [20]. As we are
achieving consistent rates of metastasis to bone implants
in our cell line models of between 60 and 80% (Fig. 4d),
bones from these donors appear to be an appropriate tis-
sue for generating a human-specific metastatic site.
Recently, understanding the role of the bone meta-
static niche for cancer cell homing to this organ has be-
come important. It is thought that metastatic cancer
cells occupy a similar/partly overlapping niche to haem-
atopoietic stem cells (HSCs) [28, 29]. Recent studies in-
vestigating the regional localisation of HSCs within the
bone marrow has identified their preference for endos-
teal regions [29, 30] due to the high cellular composition
of osteoblasts in particular. We hypothesise that cancer
cells may also be attracted to similar osteotropic signals
and have demonstrated that mobilisation of HSCs from
the niche to the circulation prior to injection of breast
cancer cell lines results in increased numbers of tumour
cells disseminated in bone [29]. Maintenance of an
osteotropic phenotype following bone core xenotrans-
plantation may, therefore, be a key strength of this
model. Examination of human B cells from the im-
planted human bone marrow migrating to the mouse
spleen indicates the functionality of the bone marrow as
well as the appropriate transfer of cells between organs.
Engraftment must therefore involve revascularisation of
the bone cores, a process that is tissue-specific. In pri-
mary patient tumour xenografts, the persistence of hu-
man vessels supporting their growth is generally poor,
with engraftment and growth associated with recruit-
ment and incorporation of the host vasculature [31],
with time frames of host vessel growth differing between
tumour type. Human skin grafts also demonstrated the
gradual replacement of human vessels by murine vessels
[32]. Revascularisation of human bone in breast cancer
models has been shown to involve vascular endothelium
of both xenograft and host species origin [14, 15], al-
though the proportions were not quantified. By dual
staining the vascular endothelium, this study demon-
strated that human immunogenic stimuli persisted in
the bone cores. As the total number of vessels in the
bone implants did not change over time, but vessels
were lined with a mixture of human and mouse
endothelial cells, this supports a mechanism of repopula-
tion of existing human vessels by the host, rather than
new mouse vessel formation. This is the first time this
has been shown in adult bone grafts.
Revascularisation of the bone implant represents an-
other variable in the efficiency of tumour colonisation in
this model, and species origin may contribute to the ini-
tial colonisation, establishment and growth of metastatic
colonies in human bone [21]. For example, in vitro stud-
ies have identified a number of molecules for the prefer-
ential adhesion of human prostate cancer [33, 34] and
breast cancer cells [35] to human endothelial cells.
These tissue-specific interactions have also been demon-
strated by the higher tumorigenicity observed in breast
cancer cells when implanted into human breast tissue at
the orthotopic site [36]. This may also be true for com-
ponents of the bone, including the bone cells (osteo-
blasts and osteoclasts) and the proteins they secrete as
well as the physical properties of the bone.
In our humanised model, we found a reduction in the
numbers of human bone cells (osteoclasts, osteoblasts
and osteocytes) in the human bone 7–14 days after im-
plantation, indicating an initial loss of viability (Fig. 1).
In this early period, blood vessels were also undergoing
graft-related changes and were not functioning or func-
tioning at low levels as indicated by the inability to traf-
fic human B cells from the bone implant to the spleen 7
days following bone engraftment (Figs. 2 and 3). By week
4 following implantation, numbers of osteoclasts and os-
teoblasts had returned to levels comparable to baseline,
new bone was actively being laid down and B cells were
being successfully transported out of the human bone
through the circulation. Interestingly, by this time point,
the majority of cells involved in bone turnover (osteo-
clasts and osteoblasts) were of mouse origin, indicating
that the resulting bone graft is a chimeric tissue com-
prised of human bone matrix complete with human-
specific bone-bound growth factors that is being remod-
elled by mouse osteoclasts and osteoblasts. The impact
of increasing ‘murinisation’ of the human bone implant
over time remains to be established. Affymetrix array
analysis of naïve (non-tumour bearing) human bone im-
planted into NOD/SCID mice for 16 weeks detected >
1000 human-specific genes (data not shown), indicating
that these implants retain human-specific RNA for long
periods of time. Human breast cancer cell lines and
PDXs also preferentially metastasised to human bone
over mouse bone. Preferential metastasis to this site was
not the result of inflammation or cytokine release during
wound healing caused by implantation surgery, as
tumour cells were only capable of metastasising to live
human bone implants (Fig. 4). Taken together, our data
suggest that human bone implants retain species-specific
properties that attract human cancer cells. These
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tumour cell-attracting factors are likely to be bound in
the bone matrix as active bone turnover is required for
metastasis to occur, but the species from which the bone
remodelling cells originate is not critical.
The importance of bone remodelling in the develop-
ment of bone metastases is further highlighted in the
ER+ and PDX models. Cells metastasised to human
bone implants but also formed metastases (although to a
lesser extent) in mouse bone. In order to stimulate
growth of the primary tumours, mice received 17β
oestradiol supplementation. Oestradiol has potent bone
anabolic properties causing increased oestoblastogenesis
and a resulting increase in osteoclast activity [17]. We
have previously shown that increasing bone cell activity
caused by oestradiol supplementation stimulates metas-
tases of MCF7 and T47D cells in mouse bone that can
be inhibited by the anti-resorptive agent zoledronic acid
[17]. We therefore hypothesise that metastasis to mouse
bone observed in our models is the result of the
oestradiol-mediated increase in bone cell activity. In the
current study, we were unable to test this hypothesis, as
we were unable to grow MCF7 or T47D in the mam-
mary ducts of NOD/SCID mice. We have previously
shown that both of these cell lines grow following ortho-
topic injection into BALB/c nude mice in the absence of
oestradiol supplementation, and Sflomos et al. have
demonstrated increased growth of ER+ve cells following
intraductal compared with orthotopic injection in SCID/
beige and NOD/SCID Gamma mice [17, 37]. The mam-
mary ducts in some strains of mice may therefore be
more permissive for the growth of ER+ve breast tu-
mours, than others. It would be useful to test this in
more detail before further refining our ER+ve breast
cancer bone metastasis models. Metastasis to the human
bone implant may not require the additional stimulus of
oestradiol. Mice injected with MDA-MB-231 (in the
current study) or SUM1315 used in previous studies did
not receive oestradiol supplementation, and these cells
lines specifically metastasised to human bone implants
[14]. Furthermore, breast cancer cells all preferentially
metastasised to human bone compared with mouse
bone, emphasising the likelihood of species-specific fac-
tors driving human breast cancers to metastasise to hu-
man bone. The identification of these factors requires
further investigation.
Unlike breast cancer cell lines, PDXs that metastasised
from the primary site did not exclusively metastasise to
bone. BB3RC32 and BB2RC08 preferentially metasta-
sised to bone; however, all metastatic PDXs spread to
the lungs and BB3RC31 and BB6RC37 preferentially
metastasised to lungs compared with bone (Tables 1 and
2). This finding was not unexpected as the PDXs chosen
for the current study had all previously been shown to
develop lung metastasis from sub-cutaneous implants in
NOD/SCID/γ mice [18]. Importantly, all PDXs retained
their hormone receptor status throughout the experi-
ment, PDXs that expressed ER, PR and/or HER2 in the
original PDX continued to express these receptors in
primary and metastatic tumours produced developed in
this humanised model (Additional file 2: Figure S2).
Breast cancer bone metastasis is currently incurable.
The ability to develop new and effective treatments is
dependent on researchers gaining an in-depth under-
standing of how tumour cells progress through the
metastatic process and how they interact with their host
environment. We have demonstrated that both breast
cancer cell lines and PDXs undergo significant genetic
changes during this multistep process: Despite being a
clonal cancer cell line, 50 genes were altered between
MDA-MB-231 TdTomato Luc2 mammary tumours that
spontaneously metastasised to human bone implants
compared with mammary tumours that did not metasta-
sise (Additional file 4: Table S1). A further 1217 genes
were changed between metastatic mammary tumours
(primary) and their corresponding metastatic deposits
isolated from the human bone implants (Additional file
3: Figure S3C). Importantly, follow-up analysis by real-
time PCR confirmed that a number of genes associated
with osteomimicry (CTSK, SPP1 and RANK) were up-
regulated in ER+ and triple-negative breast cancer cell
lines and PDXs that had metastasised to bone, compared
with their associated primary tumours [38]. In addition,
proteins that have previously been associated with in-
creased bone metastasis including the calcium-binding
protein and fibroblast marker S100A4 as well as the cell
adhesion molecule fibronectin [11] were both increased
in bone metastases from ER+ and triple-negative PDXs
compared with the primary tumour, and γ catenin, pre-
viously shown to be dysregulated in ER+ models of bone
metastasis [39], was increased in the bone metastatic de-
posits from ER+ PDXs but not triple negative. These
data support the phenotypical changes observed between
PDXs appearing more epithelial-like when growing in
the primary site but changing to a more fibroblastic ap-
pearance following metastasis to human bone implants
(Fig. 5). Importantly, this model identified cytokine-
cytokine receptor interactions as being principle drivers
of bone metastasis. Our new data indicate that IL-1B is
increased in both the primary and metastatic site prior
to the onset of metastasis and blocking activity of the
IL1R inhibits development of bone metastasis. The data
are in line with our previously published research in
which we identified IL-1B as being upregulated in mam-
mary tumours that metastasised to human bone com-
pared with mammary tumours that did not metastasise
[10, 11]. Furthermore, analysis of IL-1B expression in
tumour samples from > 1000 patients with stage II/III
breast cancer revealed that patients whose primary
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tumours expressed IL-1B were significantly more likely
to develop metastasis to bone (p = 0.017) or other organs
(p = 0.0016) compared with patients whose tumours did
not express IL-1B, over a 10-year follow-up period [10].
Whether increased IL-1B in the bone environment
primes the bone metastatic niche and/or stimulates
tumour cells to home to this organ remains to be estab-
lished. Our previous data suggests that inhibiting IL-1
does not inhibit tumour cell homing to this environ-
ment, but prevents outgrowth of disseminated tumour
cells in bone by inhibiting expansion of the bone meta-
static niche [10, 40]. It therefore appears that increased
IL-1B, observed in bone metastasis, may stimulate the
niche leading to outgrowth tumour cells disseminated in
this site. Taken together, these data suggest that in our
humanised mouse model of bone metastasis, tumour
cells that have metastasised to bone behave in a similar
manner to those previously described for other model
systems and human patients [10, 11, 41]. We are there-
fore confident that this model of human breast cancer
metastasis to human bone implants represents a clinic-
ally relevant model for the future development and test-
ing of new treatments for breast cancer bone metastasis.
Conclusions
We have developed the first PDX models of ER+ and
ER-ve breast cancers that grow at the primary site and
spontaneously metastasise to a human bone environ-
ment with high frequency and reproducibility. Breast
cancer cells utilised in these models undergo clinically
relevant molecular changes as they progress through dif-
ferent stages of the metastatic process. This model can
successfully identify metastatic drivers of breast cancer
bone metastasis and may therefore represent a useful
model for generating data that is translatable from the
laboratory to the clinic.
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Additional file 1: Figure S1. Spontaneous metastasis of T47D cells
from mouse mammary ducts to human bone implants and mouse bone.
Intra nipple injection of T47D cells into NOD SCID mice supplemented
with 4 mg/L 17β oesteradiol results in tumour growth at the primary site.
8-weeks after resection of primary tumours metastases were detected in
both human bone implants and mouse hind limbs.
Additional file 2: Figure S2. Confirmation of ER/PR/HER2 expression in
PDX samples. Gene expression analysis of estrogen receptor (ESRRG),
progesterone receptor (PGR) and HER2 (ERBB2) in PDX’s growing in the
mammary gland and in metastatic deposits isolated from human bone
implants. Histograms show mean delta CT +/− SD of the expression of
gene of interest compared with the housekeeping gene GAPDH.
Additional file 3: Figure S3. Alterations in molecular pathways
associated with bone metastasis. Heat map showing primary molecular
pathways altered in MDA-MB-231 cells that have metastasised to human
bone implants compared with the corresponding mammary tumours as
assessed on whole genome Affymetrix arrays, analysed using DAVID (A).
The number of genes altered between primary tumours that metasta-
sised to bone compared with those that did not and the number of
genes that changes between met static and non-met static primary tu-
mours and bone metastases are shown in B. Panel C, shows the genetic
pathways altered between primary tumours that metastasised to bone
and metastatic deposits isolated from human bone implants.
Additional file 4: Table S1. Affymetrix array analysis showing genetic
alterations between MDA-MB-231 cells that metastasise to human bone
compared to cells that do not metastasise.
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